* Pacific Biosciences of California Inc PACB.OQ
PACB.O is
expected to show a fall in quarterly revenue when it reports
results on February 13 for the period ending December 31 2024
* The Menlo Park California-based company is expected to
report a
31.2% decrease in revenue to $40.16 million from $58.36 million
a year ago, according to the mean estimate from 14 analysts,
based on LSEG data.The company's guidance on November 7 2024,
for the period ended December 31, was for revenue between $39.97
million and $40.37 million.
* LSEG's mean analyst estimate for Pacific Biosciences of
California Inc is for a loss of 21 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $2.50, above its last closing
price of $1.33.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.24 -0.22 -0.22 Met 2
Jun. 30 2024 -0.24 -0.23 -0.64 Missed -175.1
Mar. 31 2024 -0.28 -0.28 -0.29 Missed -5.3
Dec. 31 2023 -0.29 -0.29 -0.31 Missed -8.7
Sep. -0.34 -0.33 -0.26 Beat 20.8
30 2023
Jun. 30 2023 -0.32 -0.32 -0.28 Beat 12.7
Mar. 31 2023 -0.33 -0.33 -0.36 Missed -8.3
Dec. 31 2022 -0.37 -0.36 -0.37 Missed -2.4
This summary was machine generated February 11 at 21:03 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)